Background/rationale Long‐term treatment with anticholinergic agents may increase the risk
of cognitive impairment or dementia. This systematic literature review and meta‐analysis …

Introduction: Anticholinergics are a class of medicines that block the neurotransmitter,
acetylcholine, in the brain and peripheral tissues. Medicines with anticholinergic activity are …

Objectives To estimate the association between the duration and level of exposure to
different classes of anticholinergic drugs and subsequent incident dementia. Design Case …

Globally, the number of drug prescriptions is increasing causing more adverse drug events,
which is now a significant cause of mortality, morbidity, and disability that has reached …

Background/objectives: Available metrics for characterizing cumulative anticholinergic
exposure over time may not be well suited for use across all US data sources. In this review …

Purpose Older people are at risk of anticholinergic side effects due to changes affecting drug
elimination and higher sensitivity to drug's side effects. Anticholinergic burden scales (ABS) …

Abstract Background The Drug Burden Index (DBI) measures an individual's total exposure
to anticholinergic and sedative medications. This systematic review aimed to investigate the …

Introduction Polypharmacy is commonly associated with adverse health outcomes. There
are currently no meta-analyses of the prevalence of polypharmacy or factors associated with …

Interpreting results from deprescribing interventions to generate actionable evidence is
challenging owing to inconsistent and heterogeneous outcome definitions between studies …

Abstract Purpose The Drug Burden Index (DBI) is a non-invasive method to quantify patients'
anticholinergic and sedative drug burden from their prescriptions. This systematic review …